Empagliflozin and Other SGLT2 Inhibitors Show Cardioprotective Benefits
Since the landmark EMPA-REG OUTCOME trial, sodium–glucose cotransporter 2 (SGLT2) inhibitors have rapidly shifted from diabetes drugs to a central ...
Since the landmark EMPA-REG OUTCOME trial, sodium–glucose cotransporter 2 (SGLT2) inhibitors have rapidly shifted from diabetes drugs to a central ...
In a comprehensive cohort study published recently in JAMA Network Open, researchers have identified a subtle yet noteworthy association between ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine